Dr. Michael T. Lin, MD
Dermatology (Dermatology Physician)
15477 Ventura Blvd, Suite 100
Sherman Oaks, CA 91403
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 611
Licensed in California since 2002, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Baylor College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
CA license A77571 (first issued 2002; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Md Solutions Medical Corp (10 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 611
- Services billed
- 24,050
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 11,400 | 38 |
| Established patient office or other outpatient visit, 20-29 minutes | 526 | 267 |
| Destruction of precancer skin growth, 2-14 growths | 526 | 94 |
| Established patient office or other outpatient visit, 30-39 minutes | 481 | 269 |
| Destruction of precancer skin growth, 1 growth | 190 | 137 |
| New patient office or other outpatient visit, 45-59 minutes | 159 | 159 |
| Biopsy of related skin growth, first growth | 138 | 118 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 99 | 26 |
| New patient office or other outpatient visit, 30-44 minutes | 97 | 97 |
| Destruction of skin growth, 1-14 growths | 95 | 58 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 143 payments worth $3,862 in total to this clinician.
| Food and Beverage | $3,763 |
|---|---|
| Education | $99.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Apr 18, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 5 companies. The companies reported $470,117 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Active, not recruiting · NCT06407934 - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Sanofi US Services Inc. · Completed · NCT06181435 - A phase 3 randomized doubleblind 52WEEK placebocontrolled multicenter study with a doubleblind 52WEEK extension period with randomized dose updose down titration investigating the efficacy safety and tolerability of r…
Pfizer Inc. - Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
Sanofi US Services Inc. · Active, not recruiting · NCT05492578 - Presto characterization and clinical outcomes of alopecia aerata aa patients treated with ritlecitinib in a realworld rw cohort a multinational prospective observational study
Pfizer Inc. - A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
UCB SA · Completed · NCT05277571 - Observation priority e short - lebrikizumab - atopic dermatitis
Eli Lilly and Company - A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis …
Amgen Inc. - A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.